Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.
Safety Controls IPO opens today. Check GMP, price band, subscription and other details
Safety Controls and Devices’ Rs 48 crore IPO opened with a flat grey market premium, signaling cautious investor sentiment. The company, an EPC player in